Bellevue Asset Management AG

Bellevue Asset Management AG is a Swiss investment management firm headquartered in Küsnacht, in the canton of Zurich, and is part of the Bellevue Group. The firm is widely recognized as a specialist in healthcare and life-sciences investing, managing a suite of listed and institutional vehicles with mandates focused on biotechnology, global healthcare, and related themes. Flagship strategies include the well-known BB Biotech AG investment company and other sector-focused funds and mandates targeting medtech and broader healthcare equities. As a foreign institutional investment manager, Bellevue Asset Management AG files quarterly holdings reports with the U.S. Securities and Exchange Commission under CIK #0001642343. These Form 13F filings disclose the firm’s reportable long positions in U.S.-listed equities and ADRs over which it has investment discretion, primarily representing the U.S. component of global healthcare and biotech portfolios. The filings exclude local Swiss and other non-U.S. listings, as well as any fixed income, cash, or derivatives exposures. When organized into a multi-period 13F Portfolio Composition dataset, they provide a regulator-defined lens on how Bellevue’s healthcare expertise is expressed in U.S.-traded securities over time.

Bellevue Asset Management’s core competence lies in fundamental, bottom-up healthcare investing. Dedicated sector teams focus on sub-areas such as biotechnology, pharmaceuticals, medical technology, healthcare services, and tools and diagnostics. The research process emphasizes scientific and clinical understanding, competitive positioning, management quality, balance-sheet strength, and realistic addressable-market and profitability assumptions. The style can be described as high-conviction growth and quality within the healthcare sector. Portfolios typically combine: - Innovative biotechnology companies with differentiated pipelines or platforms. - Established pharmaceutical and specialty pharma names with durable franchises and cash flows. - Medtech and diagnostics businesses benefiting from structural trends in procedures, minimally invasive technologies, and personalized medicine. - Healthcare services and managed-care companies positioned to benefit from demographic change and efficiency pressures. Position sizing reflects upside potential, risk (clinical, regulatory, reimbursement), liquidity, and correlation within the overall healthcare book. The approach is benchmark-aware but not index-hugging; sector weights in the 13F universe are inherently skewed toward health-care subindustries, with relatively little exposure to non-healthcare sectors beyond occasional holdings in technology or industrial companies whose primary growth driver is health-related. Turnover is moderate: core convictions are held over multi-year horizons, while smaller or earlier-stage names may be resized as data readouts, regulatory milestones, or competitive dynamics evolve.

Viewed through its SEC filings under CIK #0001642343, Bellevue Asset Management AG presents as a focused healthcare and life-sciences specialist deploying concentrated, fundamentally researched portfolios in global and U.S.-listed health-care equities. The 13F record confirms strong and persistent healthcare sector concentration, multi-cap exposure within biotech, pharma, medtech, and services, and moderate turnover consistent with a long-horizon conviction approach. For institutional allocators, structuring Bellevue’s U.S. holdings into a continuous 13F History and analyzing them via a Portfolio Simulator or related Backtesting Service offers a disciplined, holdings-based assessment of implementation. Patterns in 13F Portfolio Composition—such as the balance between biotech and more diversified healthcare names, shifts in exposure around key regulatory or policy periods, and the evolution of top holdings—can be linked to a reconstructed healthcare Volatility Profile, Historical Track Record, and implied Sharpe Ratio. Together, these analytics help clarify how Bellevue’s specialized healthcare sleeve has behaved across different market and policy regimes and how that behavior compares with healthcare benchmarks and broader equity indices. Because Form 13F covers only the U.S.-listed portion of Bellevue Asset Management AG’s strategies, these diagnostics should be integrated with a fuller understanding of its non-U.S. holdings, mandate guidelines, liquidity and risk controls, and firm-level views on innovation and regulation in healthcare. As therapeutic modalities, reimbursement frameworks, and investor sentiment toward healthcare and biotech continue to evolve, an important question for allocators is how sensitive Bellevue’s high-conviction healthcare portfolios will be to future regime shifts—and how that regime sensitivity should be balanced within a diversified, multi-manager global equity allocation.

Bellevue’s risk profile is shaped by its intentional concentration in healthcare and life sciences. While portfolios are diversified across subsectors and market caps within healthcare, they are not sector-neutral versus broad equity indices. Key risk dimensions in the U.S. 13F sleeve include: - Sector concentration and thematic risk – With a substantial portion of capital in healthcare, portfolio behavior is closely tied to industry-wide sentiment, regulatory developments (FDA decisions, drug-pricing debates), reimbursement changes, and shifts in scientific paradigms, particularly in biotech. - Event and binary risk – Biotechnology holdings, especially small- and mid-cap names, are sensitive to clinical trial outcomes, regulatory approvals, safety signals, and partnership or M&A activity. These events can drive large, idiosyncratic moves in individual positions. - Style and factor exposure – The emphasis on long-term growth, innovation, and quality balance sheets results in persistent tilts toward growth and quality factors, which can underperform in value-led or commodity-driven markets but typically benefit when investors prize earnings visibility and secular growth. Within this concentrated framework, Bellevue manages risk by diversifying across development stages (commercial vs. pipeline-heavy), therapeutic areas, and business models, and by calibrating position sizes to the magnitude of binary risk. Nevertheless, when viewed as a standalone equity allocation, a reconstructed Volatility Profile based on 13F holdings will generally show higher volatility and deeper drawdowns than broad, multi-sector indices, particularly in periods of healthcare policy uncertainty or biotech risk-off. Using historical 13F filings, allocators can map Bellevue’s disclosed positions to underlying price histories and replay the portfolio through time in a Portfolio Simulator or Backtesting Service. Normalized to a user-defined notional, this reconstruction yields an indicative Historical Track Record for the U.S.-listed healthcare sleeve—highlighting its behavior across clinical data cycles, policy debates on drug pricing, interest-rate shifts affecting long-duration growth assets, and broader risk-on/risk-off regimes. From that capital trajectory, one can derive risk-adjusted diagnostics, including an implied Sharpe Ratio, as a proxy for the efficiency of the visible long-equity implementation.